Drug-induced psychosis in Parkinson's disease (II): atypical neuroleptics

Summary In this second part of a review on drug-induced psychosis in Parkinson's disease, the characteristics of typical and atypical neuroleptics will be compared and the therapeutic efficacy and the extrapyramidal side-effects of ‘atypical’ antipsychotic drugs will be discussed. These drugs affect serotonergic, adrenergic as well as dopaminergic neurotransmission and are best distinguished from the typical neuroleptics on the basis of the relationship between strong 5-HT2 and weak D2 affinities. Their succes may rely on this spectrum of effects. Clozapine, being the first choice, will be discussed in more detail.

[1]  C. Waters,et al.  Clozapine Treatment of Parkinsonism with Psychosis , 1993, Journal of the American Geriatrics Society.

[2]  E. Melamed,et al.  Ondansetron for hallucinosis in advanced Parkinson's disease , 1993, The Lancet.

[3]  R. J. Helscher,et al.  Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[4]  L. Cote,et al.  Treatment of drug-induced psychosis in Parkinson's disease with clozapine. , 1993, Advances in neurology.

[5]  M. Launer.  Diarrhoea during treatment with clozapine. , 1992, BMJ.

[6]  G. Bonney,et al.  Analgesia after surgery. , 1992, BMJ.

[7]  J. Liukkonen,et al.  Clinical picture and long-term course of epileptic seizures that occur during clozapine treatment , 1992, Psychiatry Research.

[8]  A. Ogilvie,et al.  Clozapine and hyponatraemia , 1992, The Lancet.

[9]  S. Braman,et al.  Polyserositis associated with clozapine treatment. , 1992, The American journal of psychiatry.

[10]  P. Hanno,et al.  Clozapine-induced priapism. , 1992, The Journal of urology.

[11]  N. Moore,et al.  The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. , 1992, The Journal of pharmacology and experimental therapeutics.

[12]  E. Rüther,et al.  Life-Threatening Allergic Reaction to Clozapine , 1992, British Journal of Psychiatry.

[13]  R. M. Murray,et al.  Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia , 1992, The Lancet.

[14]  H. Meltzer,et al.  In vivo occupancy of dopamine receptors by antipsychotic drugs. , 1992, Archives of general psychiatry.

[15]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[16]  R E Litman,et al.  Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. , 1992, Archives of general psychiatry.

[17]  P. Krupp,et al.  Clozapine-Associated Agranulocytosis: Risk and Aetiology , 1992, British Journal of Psychiatry.

[18]  J. Gerlach,et al.  Clozapine and D1/D2 Antagonism in Extrapyramidal Functions , 1992, British Journal of Psychiatry.

[19]  J. Peuskens,et al.  Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study , 1992, Acta psychiatrica Scandinavica.

[20]  Geetha Joseph,et al.  HLA-B38 and Clozapine-induced Agranulocytosis , 1992, Annals of Internal Medicine.

[21]  J. C. Stoof,et al.  The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. , 1992, European journal of pharmacology.

[22]  J. Tiihonen,et al.  Eosinophilia associated with clozapine , 1992, The Lancet.

[23]  F. Müller-Spahn.  RISPERIDONE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS: AN INTERNATIONAL DOUBLE‐BLIND PARALLEL‐GROUP STUDY VERSUS HALOPERIDOL. , 1992, Clinical neuropharmacology.

[24]  S. Factor,et al.  Clozapine prevents recurrence of psychosis in Parkinson's disease , 1992, Movement Disorders.

[25]  J A Lieberman,et al.  A Report of Clozapine-Induced Agranulocytosis in the United States , 1992, Drug safety.

[26]  J. Lieberman,et al.  Anticholinergic delirium caused by retreatment with clozapine. , 1991, The American journal of psychiatry.

[27]  H. Meltzer,et al.  Effects of antipsychotic drugs on serotonin receptors. , 1991, Pharmacological reviews.

[28]  M. Gastpar,et al.  Trimipramine: Pharmacological reevaluation and comparison with clozapine , 1991, Neuropharmacology.

[29]  R. Watts,et al.  Clozapine is beneficial for psychosis in Parkinson's disease , 1991, Neurology.

[30]  C. Marsden,et al.  Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol , 1991, British journal of pharmacology.

[31]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[32]  A. Cools,et al.  The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. , 1991, European journal of pharmacology.

[33]  Daniel E. Casey,et al.  Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia , 1991, Schizophrenia Research.

[34]  O. Devinsky,et al.  Clozapine‐related seizures , 1991, Neurology.

[35]  R. Remick,et al.  Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis , 1990, Neurology.

[36]  C. Durand,et al.  A controlled dose‐ranging study of remoxipride and haloperidol in schizophrenia ‐ a Canadian multicentre trial , 1990, Acta psychiatrica Scandinavica. Supplementum.

[37]  T. Lewander,et al.  Clinical profile of remoxipride ‐ a combined analysis of a comparative double‐blind multicentre trial programme , 1990, Acta psychiatrica Scandinavica. Supplementum.

[38]  J. Chiles,et al.  Weight gain associated with clozapine. , 1990, The American journal of psychiatry.

[39]  H. Baas,et al.  Treatment of parkinsonian tremor with clozapine , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[40]  R. Pfeiffer,et al.  Clozapine for psychosis in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[41]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[42]  J. Friedman,et al.  Clozapine in the treatment of psychosis in Parkinson's disease , 1989, Neurology.

[43]  R. Tandon,et al.  Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. , 1989, Archives of general psychiatry.

[44]  D. Calne,et al.  Clozapine: an antipsychotic agent in Parkinson's disease? , 1989, Clinical neuropharmacology.

[45]  K. Østergaard,et al.  Clozapine treatment of drug‐induced psychotic symptoms in late stages of Parkinson's disease , 1988, Acta neurologica Scandinavica.

[46]  S. Marini,et al.  Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent , 1986 .

[47]  J. Arnt,et al.  Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. , 2009, Acta pharmacologica et toxicologica.